Advanced Prostate Cancer Presenting as Epistaxis Only: A Case Report and Literature Review
Journal of Cancer Treatment and Research
Volume 2, Issue 6, November 2014, Pages: 61-63
Received: Dec. 13, 2014;
Accepted: Dec. 23, 2014;
Published: Jan. 4, 2015
Views 3025 Downloads 236
Usman Mohammed Tela, Urology unit, Department of Surgery, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
Audu Abdullahi Bukar, Department of Haematology, Universiy of Maiduguri Teaching Hospital, Maiduguri, Nigeria
Mala Bukar Sandabe, Department of Ear, Nose and Throat (ENT), University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
Theophilus Maksha Dabkana, Departtment of Orthopedics, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
Alhaji Bukar Musa, Department of Histopathology, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
Abubakar Sadiq Adamu, Department of Anaesthesia, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
Although Prostate cancer is the most frequently diagnosed cancer among men globally, its primary presentation as Epistaxis alone is quit uncommon. Epistaxis has numerous causes and hence poses early diagnostic challenge. We report a case of 68 year old man who presented with recurrent epistaxis as the main complaint .He was thoroughly evaluated and concluded to have a background asymptomatic advanced prostate cancer with isolated thrombocytopenia. He responded to blood transfusion and combined therapy form of Anti-androgen Deprivation Therapy. High index of suspicion is of paramount importance towards achieving early diagnosis of this unusual presentation.
Usman Mohammed Tela,
Audu Abdullahi Bukar,
Mala Bukar Sandabe,
Theophilus Maksha Dabkana,
Alhaji Bukar Musa,
Abubakar Sadiq Adamu,
Advanced Prostate Cancer Presenting as Epistaxis Only: A Case Report and Literature Review, Journal of Cancer Treatment and Research.
Vol. 2, No. 6,
2014, pp. 61-63.
Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc. Mar 1999; 91(3):159-64
Mohammed AZ, Edino ST, Ochicha O, Gwarzo AK, Samaila AA. Cancer in Nigeria: a 10-year analysis of the Kano cancer registry. Niger J Med. Jul-Aug 2008; 17(3):280-4
Badmus TA, Adesunkanmi AR, Yusuf BM, et al. Burden of prostate cancer in southwestern Nigeria. Urology. Aug 2010; 76(2):412-6.
Olapade-Olaopa E Oluwabunmi, Obamuyide H Adebayo, Yisa Gloria T. Management of advanced prostate cancer in Africa. CJU,2008;15(1):3890-3898
Randall DA, Freeman SB: Management of anterior and posterior epistaxis; Am Fam Physician. 1991 Jun;43(6):2007-14.
Mehmet Ali Erkurt, Emin Kaya, Ilhami Berber, Mustafa Koroglu, Irfan Kuku, Thrombocytopenia in Adults: Review Article, J Haematol Volume 1, Number 2-3, June 2012, pages 44-53
Anner RM, Drewinko B: Frequency and significance of bone marrow involvement by metastatic solid tumors. Cancer. 1977;39:1337–1344
Kilickap S, Erman M, Dincer M, Aksoy S, Hakan H, Yalcin Y. Bone marrow metastasis of solid tumors: clinicopathological evaluation of 73 cases. Turk J Cancer. 2007;37(3):85–88
Salako AA, Arowolo OA, Omonisi EA, Adisa AO, Titiloye NA, Adelusola K: Incidental carcinoma of the prostate gland presenting with initial manifestation of disseminated intravascular coagulopathy (dic) in a middle aged man: a case report. Cases J. 2009 Sep 29; 2:144. doi: 10.1186/1757-1626-2-14
Lim H Y, Agarwal A M, Agarwal N, Ward J H: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer, Singapore Med J 2009; 50(5) : e178
de la Fouchardière C, Flechon A, Droz JP: Coagulopathy in prostate cancer; Neth J Med 2003 Nov;61(11 ):347-54.
Ignacio Duran, Ian F Tannock: Disseminated Intravascular Coagulation as the Presenting Sign of Metastatic Prostate Cancer; J Gen Intern Med. 2006 November; 21(11): C6–C8
Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger: Treatment of Castration-Resistant Prostate Cancer, Campbell-Walsh Urology, 10th Edition, Vol 3, chapter 110, p.2958.
Karen A. Autio, Howard I. Scher, Michael J. Morris: Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer, Curr Treat Options Oncol. Jun 2012; 13(2): 174–188.